Antagonists of the human CCR5 receptor as anti-HIV-1 agents.: Part 2:: Structure-activity relationships for substituted 2-aryl-1-[N-(methyl)-N-(phenylsulfonyl) amino]-4-(piperidin-1-yl)butanes

被引:72
作者
Finke, PE
Meurer, LC
Oates, B
Mills, SG
MacCoss, M
Malkowitz, L
Springer, MS
Daugherty, BL
Gould, SL
DeMartino, JA
Siciliano, SJ
Carella, A
Carver, G
Holmes, K
Danzeisen, R
Hazuda, D
Kessler, J
Lineberger, J
Miller, M
Schleif, WA
Emini, EA
机构
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Immunol Res, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Antiviral Res, W Point, PA 19486 USA
关键词
D O I
10.1016/S0960-894X(00)00639-9
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
(2S)-2-(3,4-Dichlorophenyl)-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-[spiro(2,3-dihydrobenzthiophene-3,4'-piperidin-1'-yl)]butane S-oxide (3) has been identified as a potent CCR5 antagonist lead structure having an IC50 = 35 nM. Herein, we describe the structure-activity relationship studies directed toward the requirement for and optimization of the C-2 phenyl fragment. The phenyl was found to be important for CCR5 antagonism and substitution was limited to small moieties at the 3-position (13 and 16. X=H, 3-F, 3-Cl, 3-Me). (C) 2001 Published by Elsevier Science Ltd.
引用
收藏
页码:265 / 270
页数:6
相关论文
共 22 条
  • [1] Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures
    AbdelMagid, AF
    Carson, KG
    Harris, BD
    Maryanoff, CA
    Shah, RD
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (11) : 3849 - 3862
  • [2] Human chemokines: An update
    Baggiolini, M
    Dewald, B
    Moser, B
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 675 - 705
  • [3] Chemokine receptors and HIV-1: An attractive pair?
    Bates, P
    [J]. CELL, 1996, 86 (01) : 1 - 3
  • [4] HIV-1 entry - an expanding portal for drug discovery
    Blair, WS
    Lin, PF
    Meanwell, NA
    Wallace, OB
    [J]. DRUG DISCOVERY TODAY, 2000, 5 (05) : 183 - 194
  • [5] Host factors in the pathogenesis of HIV disease
    Cohen, OJ
    Kinter, A
    Fauci, AS
    [J]. IMMUNOLOGICAL REVIEWS, 1997, 159 : 31 - 48
  • [6] IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS
    CONDRA, JH
    SCHLEIF, WA
    BLAHY, OM
    GABRYELSKI, LJ
    GRAHAM, DJ
    QUINTERO, JC
    RHODES, A
    ROBBINS, HL
    ROTH, E
    SHIVAPRAKASH, M
    TITUS, D
    YANG, T
    TEPPLER, H
    SQUIRES, KE
    DEUTSCH, PJ
    EMINI, EA
    [J]. NATURE, 1995, 374 (6522) : 569 - 571
  • [7] Current evidence and future directions for targeting HIV entry - Therapeutic and prophylactic strategies
    D'Souza, MP
    Cairns, JS
    Plaeger, SF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (02): : 215 - 222
  • [8] Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
    Dorn, CP
    Finke, PE
    Oates, B
    Budhu, RJ
    Mills, SG
    MacCoss, M
    Malkowitz, L
    Springer, MS
    Daugherty, BL
    Gould, SL
    DeMartino, JA
    Siciliano, SJ
    Carella, A
    Carver, G
    Holmes, K
    Danzeisen, R
    Hazuda, D
    Kessler, J
    Lineberger, J
    Miller, M
    Schleif, WA
    Emini, EA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) : 259 - 264
  • [9] A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
    Dragic, T
    Trkola, A
    Thompson, DAD
    Cormier, EG
    Kajumo, FA
    Maxwell, E
    Lin, SW
    Ying, WW
    Smith, SO
    Sakmar, TP
    Moore, JP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5639 - 5644
  • [10] Host factors and the pathogenesis of HIV-induced disease
    Fauci, AS
    [J]. NATURE, 1996, 384 (6609) : 529 - 534